NCX1022 is an NO-releasing derivative of Hydrocortisone, which is the most widely used anti-inflammatory drug for the treatment of skin inflammation.

Product information

CAS Number: 571186-50-0

Molecular Weight: 541.59

Formula: C29H35NO9

Chemical Name: 2-{1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl}-2-oxoethyl 3-[(nitrooxy)methyl]benzoate

Smiles: CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)C1=CC(CO[N+]([O-])=O)=CC=C1

InChiKey: MBODWAULVMWNDB-UHFFFAOYSA-N

InChi: InChI=1S/C29H35NO9/c1-27-10-8-20(31)13-19(27)6-7-21-22-9-11-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-4-17(12-18)15-39-30(36)37/h3-5,12-13,21-23,25,32,35H,6-11,14-16H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Topical pre- and post-treatment with NCX1022 (3 nmol) in C57BL6 mice not only reduces ear oedema formation in a dose-dependent manner, but also is significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). NCX1022, but not Hydrocortisone, significantly inhibits granulocyte recruitment (tissue myeloperoxidase activity). Histological samples of mouse ears treated with NCX1022 show significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to Hydrocortisone-treated tissues. Post-treatment with Hydrocortisone does not modify the increased granulocyte infiltration induced by benzalkonium application, but NCX1022 reduces by 63% the myeloperoxidase (MPO) activity, producing a maximum effect at the dose of 3 nmol per ear. NCX1022 is significantly more potent than Hydrocortisone in reducing contact dermatitis-induced leukocyte adhesion, particularly at the early time points (e.g., 30-60 min after dermatitis induction).

Products are for research use only. Not for human use.